PDCD1 and metastatic melanoma: In a retrospective study, response and duration of response (DOR) of 104 patients with metastatic melanoma who received anti-PD-1 therapy, and baseline and 1-year positron emission tomography (PET) as well as computed tomography (CT) imaging were evaluated [54].